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There is a paucity of population-based studies examining incidence and survival trends in childhood bone tumours. We used high
quality data from four population-based registries in England. Incidence patterns and trends were described using Poisson regression.
Survival trends were analysed using Cox regression. There were 374 cases of childhood (ages 0–14 years) bone tumours (206
osteosarcomas, 144 Ewing sarcomas, 16 chondrosarcomas, 8 other bone tumours) registered in the period 1981–2002. Overall
incidence (per million person years) rates were 2.63 (95% confidence interval (CI) 2.27–2.99) for osteosarcoma, 1.90 (1.58–2.21)
for Ewing sarcoma and 0.21 (0.11–0.31) for chondrosarcoma. Incidence of Ewing sarcoma declined at an average rate of 3.1% (95%
CI 0.6–5.6) per annum (P¼0.04), which may be due to tumour reclassification, but there was no change in osteosarcoma incidence.
Survival showed marked improvement over the 20 years (1981–2000) for Ewing sarcoma (hazard ratio (HR) per annum¼0.95 95%
CI 0.91–0.99; P¼0.02). However, no improvement was seen for osteosarcoma patients (HR per annum¼1.02 95% CI 0.98–1.05;
P¼0.35) over this time period. Reasons for failure to improve survival including potential delays in diagnosis, accrual to trials,
adherence to therapy and lack of improvement in treatment strategies all need to be considered.
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Malignant bone tumours are the seventh most common group of
malignancies in children, comprising around 3–5% of cancers at
ages 0–14 years (Parkin et al, 1998) with an age standardised
incidence of approximately 5 per million person years in the
United Kingdom (Stiller, 2007). The majority of these tumours are
osteosarcoma or Ewing sarcoma (Stiller et al, 2006a), in the United
Kingdom 54% being osteosarcoma, 39% Ewing sarcoma, 2%
chondrosarcoma and 5% other types (Stiller, 2007). Worldwide,
trends in incidence rates for childhood bone tumours have
remained constant (McNally et al, 2001; Stiller et al, 2006a;
Magnanti et al, 2008), although a few studies have reported
increases (Ajiki et al, 1994; Gurney et al, 1996). The substantial
improvement in survival over the past 40 years (Arndt et al, 2007)
has been attributed to chemotherapy (Stiller et al, 2006a). Among
European countries
(19 countries), 5-year survival for all childhood bone tumours
improved from 37% in 1978–1982 to 63% in 1993–1997. For
osteosarcoma and Ewing sarcoma, 5-year survival also improved
from 37 to 61% and from 34 to 66%, respectively over this period
(Stiller et al, 2006a). We describe the incidence and survival from
bone tumours at ages 0–14 years in northern England and the
West Midlands during the period 1981–2002, updating previous
analyses (Cotterill et al, 2000; Stiller et al, 2006c).
MATERIALS AND METHODS
Data were included for all children registered during the period
1981–2002 by the Northern Region Young Persons’ Malignant
Disease Registry (NRYPMDR), the Yorkshire Specialist Register of
Cancer in Children and Young People (YSRCCYP), the West
Midlands Regional Children’s Tumour Registry (WMRCTR) and
the Manchester Children’s Tumour Registry (MCTR). These are
specialist registries that record cases of cancer in children and
young adults, and together cover around 35% of the 0- to 14-year-
old population in England (2001 combined census population for
0–14 year olds approximately 3250000) (Figure 1). All four
registries are population based and have very high levels of
ascertainment due to rigorous data collection procedures. Methods
of follow-up vary according to the individual registries. At the
NRYPMDR, children are actively followed up through general
practitioners and hospital records. At the YSRCCYP, children are
actively followed up through general practitioners and hospital
records every 2 years to determine health status, treatment and
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yadverse outcomes such as second malignancies or relapse. Cross-
checks with the national clinical trial databases are undertaken to
ensure trial entry status is complete. At the WMRCTR, follow-up
methods are both clinical and postal: surviving patients are seen
annually or every 2 years in clinic, and those who do not attend
have a postal questionnaire sent to their GP every 3 years. At the
MCTR, for the first 35 years (1954–late 1980s) active follow-up was
carried out by writing to hospitals, GPs and, in some instances,
patients or their parents. The MCTR also received discharge
summaries from the Christie Hospital and Royal Manchester
Children’s Hospital. From the 1980s onwards, active follow-up was
ceased as cases were flagged at the National Health Service Central
Register (NHSCR) and they continue to receive discharge
summaries and follow-up clinic letters from the two main
hospitals. The percentage of cases lost to follow-up are as follows:
NRYPMDR 0.72%, YSRCCYP less than 0.5%, WMRCTR 4.2%
(although tracing through the NHS Strategic Tracing Service has
not revealed any deaths in this group), MCTR less than 10%
(Birch, 1988; Muir et al, 1992; Cotterill et al, 2000; Feltbower et al,
2007).
Malignant bone tumours were defined as all those neoplasms in
group VIII of the International Classification of Childhood Cancer
(ICCC) (Steliarova-Foucher et al, 2005). Primary malignant bone
tumours registered between 1981 and 2002 in patients aged 0–14
years at the time of diagnosis were extracted from the four
participating English cancer registries. The diagnostic subgroups
included osteosarcomas (ICCC subgroup VIIIa), chondrosarcomas
(ICCC subgroup VIIIb), Ewing sarcomas (ICCC subgroup VIIIc),
specified malignant tumours (ICCC subgroup VIIId) and un-
specified malignant tumours (ICCC subgroup VIIIe). Secondary
and benign bone tumours were excluded from this study.
Information available for each case included demographic data
(gender, date of birth), information on the tumour (diagnosis date,
site and for NRYPMDR only, stage) and information on follow-up
(current status, date of death, date of last follow-up).
Statistical analysis
Age-specific incidence rates per million person years were
calculated based on mid-year population estimates for the study
region obtained from Office for National Statistics. Age-standar-
dised incidence rates (ASR) were calculated based on the standard
world population (Smith, 1992). Poisson regression models were
used to assess the effects on incidence rate of time period for
diagnosis (1981–1988, 1989–1995, 1996–2002), age group (0–4,
5–9, 10–14), gender and registry. Regression coefficients and
corresponding 95% confidence intervals (CIs) are reported. Five-
year survival rates were calculated for all cases diagnosed between
1981 and 2000, as follow-up was only available for all cases until
the end of 2005. Survival rates were calculated using Kaplan–Meier
estimation (Kaplan and Meier, 1958) and the differences in
survival between diagnostic groups were assessed using log-rank
tests. Cox Proportional Hazards regression analysis was used to
model the probability of survival in relation to age, gender and
year of diagnosis. Statistical significance was taken to be Po0.05 in
all analyses. All statistical analyses were performed using Stata
version 10.
RESULTS
There were 374 patients aged 0–14 years diagnosed with a
malignant bone tumour in the study region between 1981 and
2002. The ASR over the study period was 4.84 per million for all
0–14 year olds. The number of cases and age-specific incidence
rates by gender and disease type are shown in Table 1. There was
no statistical evidence for any gender differences in total bone
tumour incidence or within any of the bone tumour subgroups.
The most common malignant bone tumours diagnosed were
osteosarcoma (206 cases) and Ewing sarcoma (144 cases). These
comprised 55.1 and 38.5% of diagnoses, respectively. Other
subgroups were diagnosed in smaller numbers, with 16 chon-
drosarcoma cases (4.3% of diagnoses) and 8 other bone tumours
(2.1%). Age-standardised incidence rates per million population
years for each of the bone tumour subgroups were 2.63 (95% CI
2.27–2.99) for osteosarcoma, 0.21 (95% CI 0.11–0.31) for
chondrosarcoma, 1.90 (95% CI 1.58–2.21) for Ewing sarcoma
and 0.10 (95% CI 0.04–0.20) for the group comprising other
specified and unspecified tumours.
Bone cancer incidence was not uniform across age groups
(Table 1). Poisson regression models showed that after adjustment
for gender and time period, incidence was highest at age 10–14
years. The incidence rate ratios (IRRs) for age group 10–14 years
relative to 0–4 years were 13.21 (95% CI 6.48–26.94) for
osteosarcoma; 2.88 (95% CI 1.05–7.93) for chondrosarcoma; 3.76
(95% CI 2.23–6.33) for Ewing sarcoma and 5.19 (95% CI 1.05–
25.70) for other bone tumours. Incidence rates were also higher in
the age group 5–9 years than 0–4 years for osteosarcoma and
Ewing sarcoma. The IRRs for age group 5–9 years relative to 0–4
years were 5.96 (95% CI: 2.85–12.47) for osteosarcoma and 2.03
(95% CI: 1.16–3.55) for Ewing sarcoma.
Incidence did not differ between males and females for
osteosarcoma (P¼0.14), chondrosarcoma (P¼0.37), Ewing
sarcoma (P¼0.98) or other bone tumours (P¼0.94). Incidence
rates were also similar in all four registries.
The results of the analyses of time trends in bone tumour
incidence during 1981–2002 are shown in Table 2. After
adjustment for age and gender, there was evidence that the
incidence rate for Ewing sarcoma decreased on average by 3.1%
(95% CI 0.6–5.6) each year (P¼0.04). This rate of decline was not






Figure 1 Geographical areas covered by the specialist registries.
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yover time for osteosarcoma (P¼0.64), chondrosarcoma (P¼0.72)
or other bone tumours (P¼0.79).
Five-year survival rates by period of diagnosis by bone tumour
subgroup are shown in Table 3. In total, 57.8% (95% CI 52.5–63.0)
of 0–14 year olds diagnosed in the study region during 1981–2000
survived for at least 5 years from the date of diagnosis. The 5-year
survival rates for the bone tumour subgroups are respectively
58.8% (95% CI 51.8–65.9) for osteosarcoma, 53.3% (95% CI 26.6–
78.8) for chondrosarcoma, 54.9% (95% CI 46.4–63.3) for Ewing
sarcoma and 100% for other bone tumours. We found no
difference in survival rate between diagnostic groups (log-rank
test: P¼0.85) (Figure 2).
A Cox Proportional Hazards regression model for survival
showed that for Ewing sarcoma the risk of death was higher for
cases aged 10–14 years than for those aged 0–9 years (hazard ratio
(HR)¼1.86 95% CI 1.12–3.07; P¼0.02) (Figure 3). After adjusting
the model for age, the risk of death decreased by 5% for each year of
the study period (HR¼0.95 95% CI 0.91–0.99; P¼0.02). Survival
rates were similar for male and female Ewing sarcoma patients
(P¼0.79). The analysis of 5-year survival rates over the study
period for Ewing sarcoma shows when improvement occurred
(overall survival 37.5% of cases diagnosed in 1981–1987, 95% CI
24.8–50.1; 66.0% for 1988–1994, 95% CI 52.4–79.5; and 70.0% for
cases diagnosed in 1995–2000, 95% CI 53.6–86.4) (Table 3).
For osteosarcoma, there was no evidence that gender (P¼0.54), age
(P¼0.45) or year of diagnosis (P¼0.35) had any effect on survival.
For chondrosarcoma, neither gender (P¼0.23) nor age
(P¼0.16) had any effect on survival. There was marginally
significant evidence that year of diagnosis had an effect on
survival for chondrosarcoma, with risk of death decreasing by 10%
for each year of the study period (HR¼0.90, 95% CI: 0.80–1.02;
P¼0.09).
There was no evidence that disease site had any effect on
survival when lower limbs were compared with all other sites
(osteosarcoma P¼0.52; chondrosarcoma P¼0.71; Ewing sarcoma
P¼0.43). As stage was only available from the NRYPMDR, there
were too few patients for any further analyses to be conducted on
survival by stage.
Table 1 Number of cases and incidence rates per million per year by diagnostic group, gender and age- group, 1981–2002
a
Age 0–4 years Age 5–9 years Age 10–14 years Age 0–14 years
Diagnostic group Gender N Rate (95% CI) N Rate (95% CI) N Rate (95% CI) ASR (95% CI)
All types All persons 28 1.52 (0.96, 2.08) 108 4.66 (3.78, 5.53) 238 9.88 (8.63, 11.14) 4.84 (4.35, 5.34)
Male 15 1.59 (0.78, 2.39) 52 4.38 (3.19, 5.56) 116 9.39 (7.68, 11.10) 4.63 (3.96, 5.31)
Female 13 1.44 (0.66, 2.23) 56 4.95 (3.65, 6.25) 122 10.40 (8.56, 12.25) 5.06 (4.34, 5.79)
Osteosarcoma All persons 8 0.43 (0.13, 0.73) 60 2.59 (1.93, 3.24) 138 5.73 (4.78, 6.69) 2.63 (2.27, 2.99)
Male 4 0.42 (0.01, 0.84) 26 2.19 (1.35, 3.03) 65 5.26 (3.98, 6.54) 2.37 (1.89, 2.84)
Female 4 0.44 (0.01, 0.88) 34 3.01 (2.00, 4.02) 73 6.22 (4.80, 7.65) 2.91 (2.37, 3.46)
Chondrosarcoma All persons 2 0.11 (0.01, 0.39) 4 0.17 (0.05, 0.44) 10 0.42 (0.16, 0.67) 0.21 (0.11, 0.31)
Male 2 0.21 (0.03, 0.77) 2 0.17 (0.02, 0.61) 6 0.49 (0.18, 1.06) 0.26 (0.10, 0.42)
Female 0 0.00 (0.00, 0.00) 2 0.18 (0.02, 0.64) 4 0.34 (0.09, 0.87) 0.16 (0.06, 0.34)
Ewing sarcoma All persons 17 0.92 (0.48, 1.36) 43 1.85 (1.30, 2.41) 84 3.49 (2.74, 4.23) 1.90 (1.58, 2.21)
Male 9 0.95 (0.33, 1.58) 24 2.02 (1.21, 2.83) 41 3.32 (2.30, 4.34) 1.91 (1.47, 2.35)
Female 8 0.89 (0.27, 1.51) 19 1.68 (0.92, 2.43) 43 3.67 (2.57, 4.76) 1.88 (1.44, 2.33)
Other
b All persons 1 0.05 (0.00, 0.30) 1 0.04 (0.00, 0.24) 6 0.25 (0.09, 0.54) 0.10 (0.04, 0.20)
Male 0 0.00 (0.00, 0.00) 0 0.00 (0.00, 0.00) 4 0.32 (0.09, 0.83) 0.09 (0.03, 0.24)
Female 1 0.11 (0.00, 0.62) 1 0.09 (0.00, 0.49) 2 0.17 (0.02, 0.62) 0.11 (0.03, 0.29)
ASR¼age-standardised incidence rates; CI¼confidence interval.
aRates data include 95% CI in parentheses.
bOther specified and unspecified tumours.
Table 2 Number of cases and ASR’s per million per year by diagnostic group and time periods, 1981–2002
a
1981–1988 1989–1995 1996–2002
Diagnostic group Gender N Rate (95% CI) N Rate (95% CI) N Rate (95% CI)
All types All persons 149 5.29 (4.43, 6.15) 126 5.41 (4.46, 6.35) 99 3.82 (3.07, 4.58)
Male 66 4.58 (3.46, 5.70) 67 5.61 (4.26, 6.95) 50 3.80 (2.74, 4.86)
Female 83 6.05 (4.73, 7.36) 59 5.20 (3.87, 6.53) 49 3.85 (2.77, 4.93)
Osteosarcoma All persons 75 2.59 (2.00, 3.18) 73 3.11 (2.39, 3.82) 58 2.24 (1.66, 2.82)
Male 33 2.21 (1.45, 2.97) 33 2.73 (1.80, 3.67) 29 2.20 (1.39, 3.00)
Female 42 2.98 (2.07, 3.89) 40 3.50 (2.42, 4.59) 29 2.28 (1.45, 3.11)
Chondrosarcoma All persons 7 0.28 (0.11, 0.58) 3 0.13 (0.03, 0.37) 6 0.22 (0.08, 0.48)
Male 3 0.26 (0.05, 0.77) 3 0.25 (0.05, 0.72) 4 0.29 (0.08, 0.73)
Female 4 0.30 (0.08, 0.77) 0 0.00 (0.00, 0.00) 2 0.15 (0.02, 0.54)
Ewing sarcoma All persons 63 2.27 (1.71, 2.84) 49 2.13 (1.53, 2.73) 32 1.26 (0.82, 1.69)
Male 28 1.98 (1.24, 2.72) 30 2.55 (1.63, 3.46) 16 1.24 (0.63, 1.86)
Female 35 2.58 (1.72, 3.45) 19 1.70 (0.93, 2.46) 16 1.27 (0.64, 1.89)
Other
b All persons 4 0.15 (0.04, 0.39) 1 0.04 (0.00, 0.23) 3 0.11 (0.02, 0.32)
Male 2 0.12 (0.01, 0.45) 1 0.08 (0.00, 0.45) 1 0.07 (0.00, 0.40)
Female 2 0.18 (0.02, 0.65) 0 0.00 (0.00, 0.00) 2 0.15 (0.02, 0.54)
ASR¼age-standardised incidence rates; CI¼confidence interval.
aRates data include 95% CI in parentheses.
bOther specified and unspecified tumours.
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yInspection of Schoenfeld residuals showed that all Cox
regression models met the assumption of proportional hazards.
DISCUSSION
This study of childhood bone cancer in 0–14 year olds in northern
England and the West Midlands during the period 1981–2002
found an improvement in survival for Ewing sarcoma, but not for
osteosarcoma.
The overall incidence rate was 4.84 per million, similar to that
reported worldwide in countries with predominantly white
populations (Parkin et al, 1998; Stiller et al, 2006a). Bone tumours
in this age group have been previously reported to occur in the
United Kingdom at an incidence rate of 5 per million (Stiller,
2007). In addition, the increasing preponderance with age, the
equal occurrence of male and female cases in the ages 0–14 years
and the predominance of osteosarcoma and Ewing sarcoma found
in this study are also typical patterns reported in earlier studies
(Parkin et al, 1998; Stiller et al, 2006a).
Incidence rates were highest at ages 10–14 years. This is
consistent with previous literature, as it has been widely reported
that incidence of malignant bone tumours peak during the time of
puberty (with the peak occurring later in boys than in girls), when
children are undergoing a growth spurt and bones experience
rapid growth (Grovas et al, 1997; Martin et al, 1997; Stiller et al,
2006a).
Whereas no significant temporal change was found in the
incidence of childhood osteosarcoma, chondrosarcoma, other
specified or other unspecified bone tumours over the study
period, there was a decrease in the incidence of Ewing sarcoma.
Several recently published studies have reported that bone tumour
incidence remains stable over time in spite of an overall increase in
cases of childhood cancer (McNally et al, 2001; Stiller et al, 2006a;
Magnanti et al, 2008), with one specifically reporting stable
incidence of Ewing sarcoma for the time period 1973–2004
(Esiashvili et al, 2008). Our observed decrease in the incidence of
Ewing sarcoma remains unexplained. Although this decrease may
be real, the role of artefact cannot be excluded. In three of the four
registries (NRYPMDR, YSRCCYP, WMRCTR), there were
increases in the incidence of soft-tissue Ewing sarcoma/pPNET
Table 3 Percentage 5-year survival by time period, diagnostic group and age
a
1981–1987 1988–1994 1995–2000
Diagnostic group Gender Rate (95% CI) Rate (95% CI) Rate (95% CI)
All types All persons 51.13 (42.63, 59.62) 61.74 (52.86, 70.62) 62.37 (52.52, 72.21)
Male 57.14 (44.18, 70.10) 59.70 (47.96, 71.45) 61.90 (47.22, 76.59)
Female 46.75 (35.61, 57.90) 64.58 (51.05, 78.11) 62.75 (49.48, 76.01)
Osteosarcoma All persons 60.61 (48.82, 72.39) 58.46 (46.48, 70.44) 57.14 (44.18, 70.10)
Male 68.97 (52.13, 85.80) 58.06 (40.69, 75.44) 54.17 (34.23, 74.10)
Female 54.05 (38.00, 70.11) 58.82 (42.28, 75.37) 59.38 (42.36, 76.39)
Chondrosarcoma All persons 42.86 (9.90, 81.59) 50.00 (1.26, 98.74) 67.00 (22.28, 95.67)
Male 66.67 (9.43, 99.16) 50.00 (1.26, 98.74) 75.00 (19.41, 99.16)
Female 25.00 (0.63, 80.59) 0.00 (—) 50.00 (1.26, 98.74)
Ewing sarcoma All persons 37.50 (24.82, 50.18) 65.96 (52.41, 79.50) 70.00 (53.60, 86.40)
Male 36.36 (16.26, 56.47) 60.61 (43.93, 77.28) 71.43 (47.76, 95.09)
Female 38.24 (21.90, 54.57) 78.57 (49.20, 95.34) 68.75 (46.04, 91.46)
Other
b All persons 100.00 (39.76, 100.00) 100.00 (2.50, 100.00) 100.00 (2.50, 100.00)
Male 100.00 (15.81, 100.00) 100.00 (2.50, 100.00) 0.00 (—)
Female 100.00 (15.81, 100.00) 0.00 (—) 100.00 (2.50, 100.00)
CI¼confidence interval.
aRates data include 95% CI in parentheses.
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Figure 3 Kaplan–Meier survival for Ewing sarcoma by age. HR
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Figure 2 Kaplan–Meier survival by diagnosis group. Log-rank test for
differences between diagnostic groups; P¼0.85.
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yduring the study period. Some tumours previously classified as
Ewing may now be classified as soft tissue sarcoma.
Overall, 57.8% of cases survived for at least 5 years,
osteosarcoma (58.8%) and Ewing sarcoma (54.9%). This is slightly
lower than a recent large Europe-wide study using data from the
Automated Childhood Cancer Information System project, which
reported the 5-year survival rate as 61% for malignant bone
tumours in children aged 0–14 years in Europe during 1988–1997,
with 5-year survival of 59% for osteosarcoma and 62% for Ewing
sarcoma (Stiller et al, 2006a). Our results are also lower than those
reported in the EUROCARE-3 study analysis, which reported 66%
5-year survival for osteosarcoma and 69% for Ewing sarcoma
during the time period 1990–1994 (Gatta et al, 2003). However,
our results are in line with data from an earlier EUROCARE study,
which reported 5-year survival for malignant bone tumours in
children aged 0–14 years in England and Wales to be 43 and 45%
for osteosarcoma and Ewing sarcoma, respectively, for 1978–1989,
and 55 and 57% for 1985–1989 (Stiller et al, 2001). Poorer survival
rates may be due to failure to improve accrual into trials.
Our data show that survival from bone tumours in northern
England and the West Midlands is lower than that seen in other
European countries. Survival data comparing European regions
show northern England and the West Midlands to have lower
5-year survival than the northern, southern and western regions of
Europe, with these reporting 66, 65 and 66% 5-year survival,
respectively. Only eastern Europe, which has a 41% 5-year survival
rate, performs worse than northern England and the West
Midlands (Stiller et al, 2006a). Variations between countries may
reflect differing treatment strategies.
Five-year survival from malignant bone tumours was lower in
children in the older age group of 10–14 years than those under
the age of 10 years. Lower survival in older age groups has been
reported in several studies. However, these tended to compare
survival in adolescents aged 15–19 years with children aged 0–14
years (Stiller et al, 2006a,b). No significant survival differences by
age were observed in both a recent UK based study analysing data
from the National Registry of Childhood Tumours (Stiller, 2007)
and in a US study analysing SEER data (Ries et al, 1999). However,
our data support another US study of Ewing sarcoma, which
reports better survival below the age of 10 years than at ages 10–19
years (Esiashvili et al, 2008).
Gender was not significant in relation to survival for osteo-
sarcoma or Ewing sarcoma, as reported for Ewing sarcoma in the
United Kingdom (Stiller et al, 2006c). However, a recent study of
Ewing sarcoma from the United States of America has reported a
higher 5-year survival rate in females than males (Esiashvili et al,
2008). In addition, higher survival rates for osteosarcoma have
been reported in females than males in a few studies. This
difference between genders observed in some studies (Scranton
et al, 1975; Homa et al, 1991) may be due to poor response to
chemotherapy among males (Bielack et al, 2002).
Survival for Ewing sarcoma increased over the time period
1981–2002, whereas survival for osteosarcoma and the other
subgroups remained unchanged. Studies reporting increased
survival in both Ewing sarcoma and osteosarcoma over time
(Miller et al, 1995; Dama et al, 2006; Stiller et al, 2006a) were
concerned with earlier time periods. The most recent study of
survival trends in Ewing sarcoma reported an improvement over a
30-year period up until 2004 (Esiashvili et al, 2008). The late 1970s
and early 1980s saw the introduction of chemotherapy into the
treatment of childhood bone tumours in addition to local control
through surgery and radiotherapy. This gave rise to an increase in
survival from the disease in this time period (Stiller et al, 2006a).
Treatment for childhood bone tumours has not markedly changed
since the 1980s, which may explain the subsequent hiatus in
survival improvement. However, the lack of progress in achieving
improved survival is of concern and requires further investigation
and intervention measures. The possible contribution of delay in
diagnosis to the lack of improved survival for osteosarcoma should
be recognised, as it has been confirmed that long diagnosis delays
in bone tumours are common. These long symptom durations are
due to both patients and health professionals. Several factors may
influence diagnosis delays, for example, delays may be greater for
those living in rural compared with urban areas (Schnurr et al,
2008), while the site and biology of the tumour may also determine
the extent of delay. Ewing sarcoma patients are more likely to have
a longer symptom interval than osteosarcoma due to its greater
propensity for growth in the axial skeleton. Early diagnosis and
treatment are necessary for securing a favourable outcome (Bielack
et al, 2002).
The efficacy of UK treatment regimens also needs investigation.
Despite the increase in survival for Ewing sarcoma, the United
Kingdom still lags behind Europe, and one contributing factor may
be due to the differing treatment in the United Kingdom. This
issue has been studied in a comparative survival analysis between
the United Kingdom and Germany, where lower overall 5-year
survival rates were observed in UK patients compared with those
treated in Germany. Local therapy practice appeared to be the only
explanatory factor associated with this difference in survival. For
example, a higher proportion of German patients were treated with
combined radiotherapy and surgery, reflecting a more aggressive
philosophy of treatment than in the United Kingdom (Lewis,
2006). A similar change in UK practice may therefore result in
increased 5-year survival, reducing the gap in survival with the rest
of Europe.
This study highlights the worse survival from bone tumours
overall than in other western European countries, and that, in spite
of a significant increase in survival from Ewing sarcoma, there has
been no such improvement since 1981 from osteosarcoma.
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